US FDA Hears Competing Messages On Off-Label Communications

Over the course of a two-day meeting at FDA headquarters, the agency heard from the medtech industry, which argued for expanding rights to off-label promotion, and consumer groups that worry about the possible impact on the public health. The meeting is intended to inform FDA's comprehensive review of its regulations and policies governing firms' communications about unapproved uses of approved/cleared products.

As FDA continues its wholesale review of policies governing off-label communications by device and drug companies, the agency got an earful on both sides of the issue at two-day public hearing held at its headquarters. At the Nov. 9-10 gathering, manufacturers asked for much more freedom to disseminate off-label information while patients and patient advocates expressed concern the move could endanger the public health.

The meeting took place in the context of a string of court decisions that have pushed back on FDA's interpretation...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Medtech M&A Resurges: How To Define Startup Exit Strategy

24 Jul 2025

• By Natasha Barrow

The medtech M&A landscape is experiencing a resurgence fueled by significant capital from private equity and venture firms, says Alex Wakefield, CRO of AcuityMD. Building strong relationships with physicians remains crucial in medtech, and defining an exit strategy early is imperative.

HHS Suggests Drastic Reductions To Skin Substitute Payments

23 Jul 2025

• By Elizabeth Orr

The US Department of Health and Human Services has proposed cutting Medicare reimbursement for skin substitutes used in chronic wound care by up to 90%. The change aims to address rising costs but could harm patient access and treatment quality, prompting concerns from industry stakeholders.